Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Ayala Pharmaceuticals stock opened at $0.03 on Wednesday. The company’s 50 day simple moving average is $0.03 and its 200-day simple moving average is $0.04. Ayala Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.78. The company has a market capitalization of $1.28 million, a price-to-earnings ratio of 0.00 and a beta of 1.68.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.